X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
clinical neurology (8) 8
index medicus (7) 7
multiple sclerosis (7) 7
humans (6) 6
adult (5) 5
female (5) 5
male (5) 5
natalizumab (5) 5
neurology (5) 5
neurosciences (5) 5
middle aged (4) 4
magnetic resonance imaging (3) 3
multiple sclerosis, relapsing-remitting - drug therapy (3) 3
multiple-sclerosis (3) 3
nuclear magnetic resonance--nmr (3) 3
patients (3) 3
brain atrophy (2) 2
discontinuation (2) 2
efficacy (2) 2
fingolimod (2) 2
fingolimod hydrochloride - therapeutic use (2) 2
immunologic factors - therapeutic use (2) 2
medicine & public health (2) 2
mri (2) 2
natalizumab - therapeutic use (2) 2
neuroradiology (2) 2
progressive multifocal leukoencephalopathy (2) 2
psychiatry (2) 2
research (2) 2
retrospective studies (2) 2
risk (2) 2
therapy (2) 2
treatment outcome (2) 2
young adult (2) 2
5-year follow-up (1) 1
abnormalities (1) 1
adherence (1) 1
alemtuzumab (1) 1
alemtuzumab - adverse effects (1) 1
alemtuzumab - therapeutic use (1) 1
analysis (1) 1
asymptomatic pml (1) 1
atrophy (1) 1
brain activity (1) 1
brain mapping (1) 1
brain mapping - methods (1) 1
brain research (1) 1
cells (1) 1
cingulate cortex (1) 1
clinical trials (1) 1
clinical-practice (1) 1
cluster headache (1) 1
cluster headache - physiopathology (1) 1
cognition (1) 1
cognition; italian database; natalizumab; neuropsychological impairment; progressive multifocal leukoencephalopathy; neurology; neurology; immunology; immunology and allergy; natalizumab; cognition; neuropsychological impairment; italian database (1) 1
coherence tomography (1) 1
comorbidities (1) 1
controlled trial (1) 1
copolymer 1 (1) 1
decision making (1) 1
demography (1) 1
development and progression (1) 1
discontinuation; multiple sclerosis; tysabri; neurology; neurology (1) 1
disease modifying therapies (1) 1
disease-activity (1) 1
disease-free survival (1) 1
diseases (1) 1
drug holiday (1) 1
drug therapy (1) 1
drugs (1) 1
dysfunction (1) 1
erythroblasts (1) 1
erythrocyte count (1) 1
erythropoiesis (1) 1
exercise therapy (1) 1
fatigue (1) 1
fatigue - diagnosis (1) 1
fatigue - therapy (1) 1
fluctuations (1) 1
follow-up studies (1) 1
functional connectivity (1) 1
glatiramer acetate - therapeutic use (1) 1
grey-matter (1) 1
guidelines (1) 1
image interpretation, computer-assisted (1) 1
immunologic factors - adverse effects (1) 1
impact (1) 1
injections (1) 1
interferon (1) 1
interferon beta-1a (1) 1
interferons - therapeutic use (1) 1
interruption (1) 1
intolerance (1) 1
italian database (1) 1
laboratories (1) 1
leber's hereditary optic neuropathy (1) 1
leukoencephalopathy (1) 1
logistic models (1) 1
magnetic resonance imaging - methods (1) 1
magnetic-resonance-spectroscopy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Neurology, ISSN 0340-5354, 12/2018, Volume 265, Issue 12, pp. 2851 - 2860
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 8/2019, Volume 25, Issue 9, pp. 1263 - 1272
Background: With many options now available, first therapy choice is challenging in multiple sclerosis (MS) and depends mainly on neurologist and patient... 
relapsing–remitting | persistence | Switch | naïve | disease modifying therapies | real-life | relapsing-remitting | NATALIZUMAB | NEUROSCIENCES | ADHERENCE | CLINICAL NEUROLOGY | COMORBIDITIES | DRUGS | INJECTIONS | FINGOLIMOD | naive | Intolerance | Spinal cord | Multiple sclerosis | Demography | Copolymer 1 | Nuclear magnetic resonance--NMR | Magnetic resonance imaging | Decision making | Interferon | Patients
Journal Article
Expert Review of Neurotherapeutics, ISSN 1473-7175, 04/2017, Volume 17, Issue 4, pp. 373 - 379
Introduction: Fatigue is one of the most common symptoms associated with multiple sclerosis, affecting almost 80% of patients with 55% of them reporting it as... 
treatment | Fatigue | multiple sclerosis | pathophysiology | scales | PSYCHOMETRIC PROPERTIES | BRAIN ATROPHY | PROGRESSIVE MS | SEVERITY SCALE | RANDOMIZED CONTROLLED-TRIAL | CLINICAL NEUROLOGY | IMPACT | MOTOR | PHARMACOLOGY & PHARMACY | PEOPLE | QUALITY-OF-LIFE | RASCH ANALYSIS | Multiple Sclerosis - physiopathology | Fatigue - diagnosis | Fatigue - therapy | Sleep Wake Disorders | Humans | Exercise Therapy
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 11/2019, Volume 90, Issue 11, pp. 1201 - 1206
ObjectiveTo study the effect of natural menopause on multiple sclerosis clinical course.MethodsThis was an observational, retrospective, multicentre, cohort... 
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 03/2019, Volume 90, Issue 3, pp. 261 - 267
ObjectiveEarly diagnosis of natalizumab-related progressive multifocal leucoencephalopathy (NTZ-PML) in multiple sclerosis has been deemed a major priority by... 
STATEMENT | SURVIVAL | SURGERY | ASYMPTOMATIC PML | PLASMA | MULTIPLE-SCLEROSIS | MRI | PSYCHIATRY | GUIDELINES | NATALIZUMAB-ASSOCIATED PML | RISK | CLINICAL NEUROLOGY | Neurology | Multiple sclerosis | Nuclear magnetic resonance--NMR | Brain research | Surveillance | Laboratories | Medical diagnosis | Patients | Psychiatry
Journal Article
Cephalalgia, ISSN 0333-1024, 11/2010, Volume 30, Issue 11, pp. 1383 - 1391
Journal Article
Multiple Sclerosis and Related Disorders, ISSN 2211-0348, 2014, Volume 3, Issue 4, pp. 520 - 526
Abstract Background Pivotal and post-marketing studies demonstrated the impressive efficacy and the good tolerability profile of natalizumab in Multiple... 
Neurology | Tysabri | Multiple sclerosis | Discontinuation | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | THERAPY | EFFICACY | RISK | DRUG HOLIDAY | INTERRUPTION | CLINICAL NEUROLOGY | DISEASE-ACTIVITY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.